Shalini Sharp
2017 - Ultragenyx Pharmaceutical
In 2017, Shalini Sharp earned a total compensation of $2.6M as Chief Financial Officer and Executive Vice President at Ultragenyx Pharmaceutical, a 34% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $188,315 |
|---|---|
| Option Awards | $1,541,879 |
| Salary | $455,785 |
| Stock Awards | $424,043 |
| Other | $32,697 |
| Total | $2,642,719 |
Sharp received $1.5M in option awards, accounting for 58% of the total pay in 2017.
Sharp also received $188.3K in non-equity incentive plan, $455.8K in salary, $424K in stock awards and $32.7K in other compensation.
Rankings
In 2017, Shalini Sharp's compensation ranked 4,207th out of 14,666 executives tracked by ExecPay. In other words, Sharp earned more than 71.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,207 out of 14,666 | 71st |
Division Manufacturing | 1,472 out of 5,772 | 75th |
Major group Chemicals And Allied Products | 421 out of 2,075 | 80th |
Industry group Drugs | 322 out of 1,731 | 81st |
Industry Pharmaceutical Preparations | 256 out of 1,333 | 81st |
Source: SEC filing on April 27, 2018.
Sharp's colleagues
We found five more compensation records of executives who worked with Shalini Sharp at Ultragenyx Pharmaceutical in 2017.
2017
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
2017
Jayson Dallas
Ultragenyx Pharmaceutical
Chief Commercial Officer and Executive Vice President
2017
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officers and Executive Vice President
2017
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President of Translational Sciences
2017
Karah Parschauer
Ultragenyx Pharmaceutical